PH12014500215B1 - Notch pathway signaling inhibitor compound - Google Patents

Notch pathway signaling inhibitor compound

Info

Publication number
PH12014500215B1
PH12014500215B1 PH1/2014/500215A PH12014500215A PH12014500215B1 PH 12014500215 B1 PH12014500215 B1 PH 12014500215B1 PH 12014500215 A PH12014500215 A PH 12014500215A PH 12014500215 B1 PH12014500215 B1 PH 12014500215B1
Authority
PH
Philippines
Prior art keywords
signaling inhibitor
notch pathway
pathway signaling
inhibitor compound
compound
Prior art date
Application number
PH1/2014/500215A
Other languages
English (en)
Other versions
PH12014500215A1 (en
Inventor
Philip Arthur Hipskind
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH12014500215A1 publication Critical patent/PH12014500215A1/en
Publication of PH12014500215B1 publication Critical patent/PH12014500215B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
PH1/2014/500215A 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound PH12014500215B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16
PCT/US2012/047100 WO2013016081A1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound

Publications (2)

Publication Number Publication Date
PH12014500215A1 PH12014500215A1 (en) 2014-03-17
PH12014500215B1 true PH12014500215B1 (en) 2018-09-07

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2014/500215A PH12014500215B1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound

Country Status (36)

Country Link
US (1) US8569286B2 (enExample)
EP (1) EP2736920B1 (enExample)
JP (1) JP6027110B2 (enExample)
KR (1) KR101578309B1 (enExample)
CN (1) CN103732612B (enExample)
AP (1) AP4080A (enExample)
AR (1) AR087107A1 (enExample)
AU (1) AU2012287251B2 (enExample)
BR (1) BR112014001600B1 (enExample)
CA (1) CA2841178C (enExample)
CL (1) CL2014000175A1 (enExample)
CO (1) CO6862159A2 (enExample)
CR (1) CR20140036A (enExample)
CY (1) CY1116645T1 (enExample)
DK (1) DK2736920T3 (enExample)
DO (1) DOP2014000011A (enExample)
EA (1) EA023044B1 (enExample)
EC (1) ECSP14013179A (enExample)
ES (1) ES2544937T3 (enExample)
GT (1) GT201400012A (enExample)
HR (1) HRP20150771T1 (enExample)
HU (1) HUE027534T2 (enExample)
IL (1) IL229988A (enExample)
JO (1) JO3148B1 (enExample)
MA (1) MA35611B1 (enExample)
ME (1) ME02171B (enExample)
MX (1) MX356536B (enExample)
MY (1) MY184303A (enExample)
PE (1) PE20141061A1 (enExample)
PH (1) PH12014500215B1 (enExample)
PL (1) PL2736920T3 (enExample)
PT (1) PT2736920E (enExample)
RS (1) RS54135B1 (enExample)
SI (1) SI2736920T1 (enExample)
TW (1) TWI568730B (enExample)
WO (1) WO2013016081A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350216B2 (en) 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
AU2017213628B2 (en) 2016-02-05 2021-07-29 Denali Therapeutics Inc. Inhibitors of receptor-interacting protein kinase 1
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
WO2017180385A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
MX380779B (es) * 2016-04-12 2025-03-12 Lilly Co Eli Terapia combinatoria con inhibidores notch y cdk4/6
JP7194022B2 (ja) * 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Notch阻害剤とPD-1またはPD-L1阻害剤との併用療法
US20190209581A1 (en) 2016-08-31 2019-07-11 Eli Lilly And Company Dosage regimen for treatment of solid tumors
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
WO2018107060A1 (en) 2016-12-09 2018-06-14 Denali Therapeutics Inc. Compounds, compositions and methods
AU2018222749B2 (en) 2017-02-17 2024-04-18 Fred Hutchinson Cancer Center Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
EP3703750B1 (en) 2017-11-01 2024-12-04 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
MA50564A (fr) * 2017-11-06 2020-09-16 Hutchinson Fred Cancer Res Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
MX2020011826A (es) * 2018-05-06 2021-01-15 Ayala Pharmaceuticals Inc Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
JP2022504265A (ja) 2018-10-02 2022-01-13 フリークエンシー セラピューティクス インコーポレイテッド 耳治療薬に関する医薬組成物及び方法
US20220175776A1 (en) 2019-04-08 2022-06-09 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001232A3 (en) * 1996-12-23 2001-02-28 Elan Pharmaceuticals Inc San F Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds
AU4710199A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
CA2324474A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
NZ541324A (en) 2003-02-04 2008-10-31 Hoffmann La Roche Malonamide derivatives as gamma-secretase inhibitors
KR100834177B1 (ko) 2003-09-09 2008-05-30 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
DK1673347T3 (en) 2003-10-06 2015-10-12 Hoffmann La Roche SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USED AS GAMMA SECRETASE INHIBITORS
AU2007229550B2 (en) 2006-03-27 2012-03-08 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma secretase inhibitors
CA2676160A1 (en) * 2007-02-02 2008-08-07 F. Hoffmann-La Roche Ag 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives
US20090181944A1 (en) 2008-01-11 2009-07-16 John Frederick Boylan Method for cancer therapy
US8637493B2 (en) * 2009-11-12 2014-01-28 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
AR087107A1 (es) 2014-02-12
IL229988A (en) 2017-07-31
RS54135B1 (sr) 2015-12-31
CA2841178C (en) 2016-12-20
SI2736920T1 (sl) 2015-08-31
EP2736920B1 (en) 2015-07-01
CO6862159A2 (es) 2014-02-10
MA35611B1 (fr) 2014-11-01
PE20141061A1 (es) 2014-09-06
CL2014000175A1 (es) 2014-08-22
TWI568730B (zh) 2017-02-01
JP6027110B2 (ja) 2016-11-16
CN103732612A (zh) 2014-04-16
CR20140036A (es) 2014-03-21
PH12014500215A1 (en) 2014-03-17
GT201400012A (es) 2014-07-16
MX356536B (es) 2018-06-01
MY184303A (en) 2021-03-31
US8569286B2 (en) 2013-10-29
TW201315732A (zh) 2013-04-16
NZ618891A (en) 2015-12-24
ECSP14013179A (es) 2014-03-31
EA201490161A1 (ru) 2014-04-30
BR112014001600B1 (pt) 2022-09-13
KR101578309B1 (ko) 2015-12-16
CN103732612B (zh) 2015-09-23
KR20140026624A (ko) 2014-03-05
DK2736920T3 (en) 2015-07-20
PL2736920T3 (pl) 2015-11-30
HRP20150771T1 (hr) 2015-08-28
CY1116645T1 (el) 2017-03-15
HK1194086A1 (en) 2014-10-10
BR112014001600A2 (pt) 2017-02-21
MX2014001084A (es) 2014-02-27
DOP2014000011A (es) 2014-07-31
AU2012287251A1 (en) 2014-01-30
HUE027534T2 (en) 2016-11-28
ES2544937T3 (es) 2015-09-07
JO3148B1 (ar) 2017-09-20
CA2841178A1 (en) 2013-01-31
EA023044B1 (ru) 2016-04-29
US20130029972A1 (en) 2013-01-31
ME02171B (me) 2015-10-20
AU2012287251B2 (en) 2015-05-14
AP4080A (en) 2017-03-29
WO2013016081A1 (en) 2013-01-31
EP2736920A1 (en) 2014-06-04
JP2014527042A (ja) 2014-10-09
AP2014007362A0 (en) 2014-01-31
PT2736920E (pt) 2015-09-16

Similar Documents

Publication Publication Date Title
MY184303A (en) Notch pathway signaling inhibitor compound
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
IN2014DN10670A (enExample)
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MX2011009796A (es) Inhibidores de la cinasa pi3.
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
MX362879B (es) Usos novedosos.
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
TN2013000515A1 (en) Notch pathway signaling inhibitor compound
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch